GlassScriptPhysician profile
Glen Tonnessen
NPI 1154387389
$24,459.32
in general payments reported to CMS, 2019-2025
40 companies · $855 in 2025
The $855 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,627 · 2020: $10K · 2021: $866 · 2022: $780 · 2023: $1,787 · 2024: $1,514 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,155.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $17,251.65 | 2019-2025 | Bioflo, Venacure 1470 Pro |
| Janssen Pharmaceuticals, INC | $950.33 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $838.38 | 2019-2025 | |
| Amgen INC. | $781.43 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $689.99 | 2020-2025 | Varithena Administration Pack, Watchman Flx, Watchman |
| Pfizer INC. | $499.60 | 2019-2025 | |
| Edwards Lifesciences Corporation | $453.62 | 2023-2024 | Sapien 3 Ultra Resilia, Konect Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| E.R. Squibb & Sons, L.L.C. | $345.29 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $287.54 | 2021-2025 | Verquvo |
| Tactile Systems Technology INC | $214.42 | 2019-2024 | Flexitouch Plus, Entre Plus |
| Bard Peripheral Vascular, INC. | $173.89 | 2023 | Venclose Maven Catheter |
| Esperion Therapeutics, INC. | $172.74 | 2020-2024 | Nexletol |
| Penumbra, INC. | $165.39 | 2024 | Indigo System |
| Merz North America, INC. | $151.63 | 2019 | |
| Amarin Pharma, INC. | $150.81 | 2019-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Infobionic, INC | $133.80 | 2025 | Mome Device |
| Atricure, INC. | $132.31 | 2023-2024 | |
| Biocompatibles, INC. | $113.03 | 2019 | |
| Sanofi-Aventis U.S. LLC | $112.28 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.69 | 2019-2023 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $93.79 | 2019 | |
| Philips North America LLC | $65.43 | 2022-2023 | |
| Baxter Healthcare | $56.50 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor |
| Inspire Medical Systems, INC. | $56.36 | 2023-2024 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $47.92 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $46.67 | 2022-2023 | Injectafer |
| Kiniksa Pharmaceuticals, LTD. | $44.01 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $43.60 | 2019-2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $37.49 | 2024-2025 | Onpattro |
| Lexicon Pharmaceuticals, INC. | $35.10 | 2023 | Inpefa |
| Novo Nordisk INC | $34.10 | 2024 | Wegovy |
| Medtronic, INC. | $27.36 | 2022 | |
| Organogenesis INC. | $27.01 | 2023 | Puraply |
| Cashflow Solutions, LLC | $25.36 | 2023 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
| Abiomed | $23.43 | 2025 | |
| Lilly USA, LLC | $21.23 | 2024 | Zepbound |
| Janssen Biotech, INC. | $15.10 | 2023 | Xarelto |
| Medtronic Vascular, INC. | $14.45 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.79 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Tonnessen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.